HOME >> BIOLOGY >> NEWS
Long-term ulcerative colitis study shows Remicade responders maintained improvement

WASHINGTON, DC, May 23, 2007 Findings presented today at Digestive Disease Week 2007 (DDW), from long-term extensions of the ACT trials (Active Ulcerative Colitis 1 & 2) show that subjects with moderately to severely active ulcerative colitis (UC) who had responded to REMICADE (infliximab) in the blinded phase of the trials maintained improvement in their clinical symptoms for up to two years.

The ACT extension trials were conducted in both the United States and Europe, under co-principle investigators William Sandborn, M.D. of the Mayo Clinic and Walter Reinisch, M.D., of the University Hospital Vienna, Austria. The data show that for patients who completed follow-up through week 56 of the extension trials, 92 percent reported mild or no disease activity, as measured by the Physician's Global Assessment (PGA). For patients followed through week 104, 97 percent reported mild or no disease activity.

At week 0 of the ACT extension trials, 76 percent of 229 responder patients enrolled had mild or no disease activity, as indicated by a PGA score of 0 or 1, and 41 percent had no disease activity (PGA score of 0). At week 56, 92 percent of those patients remaining in the extension trials (n=181) had mild or no disease activity, and 61 percent had no disease activity. At week 104, 97 percent of those patients remaining in the extension trials (n=97) had mild or no disease activity, and 75 percent had no disease activity.

"The data demonstrate the sustained efficacy of REMICADE for many patients with UC," said co-principle investigator Walter Reinisch, M.D., of the University Hospital Vienna, Austria. "Because UC is a chronic condition, many patients live with cycles of recurring flares. This can greatly hinder a person's social and professional life. The availability of therapies that quickly reduce symptoms and maintain response and remission long term is a significant benefit to patients."

Separate data also presented at DDW
'"/>

Contact: Melissa Katz
mkatz2@cntus.jnj.com
215-325-6875
Centocor, Inc.
23-May-2007


Page: 1 2 3

Related biology news :

1. Long-term marijuana smoking leads to respiratory complaints
2. Long-term cancer risk follows stem cell transplant recipients
3. Long-term ocean data confirm fishing puts species in double jeopardy
4. Long-term lead exposure linked to cognitive decline in older adults
5. Long-term changes in experience cause neurons to sprout new long-lasting connections
6. Long-term study shows brain function not impaired by tight diabetes control and hypoglycemia
7. Long-term ecological research should include studies on how social science interacts with ecosystems
8. Long-term memory controlled by molecular pathway at synapses
9. Scientists find gene target that may protect against Crohns disease and ulcerative colitis
10. Data show treatment with Remicade reduced hospitalizations for ulcerative colitis patients by half
11. Data in New England Journal of Medicine show benefits of REMICADE in ulcerative colitis patients

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/1/2020)... N.J. (PRWEB) , ... July 01, 2020 , ... ... announced that it had completed the purchase of Teva-Takeda Pharmaceuticals’ packaging facility in ... the company’s existing Japanese clinical supply facility located in Kakegawa, the new 60,000-square-foot ...
(Date:6/28/2020)... ... June 25, 2020 , ... In an upcoming episode scheduled for the fall ... Care Testing solutions (POCT). Check local listings for more info. , Today, the majority ... are shipped to labs throughout the country. Results are then available several days later. ...
(Date:6/23/2020)... ... June 23, 2020 , ... First Aid Africa, a ... UK supplier and manufacturer of innovative portable renewable energy equipment, have announced the ... against the COVID-19 pandemic in Zambia. , One of Renovagen’s FAST FOLD portable ...
Breaking Biology News(10 mins):
(Date:7/18/2020)... ... July 17, 2020 , ... ... for the life sciences and food industries, is pleased to announce that Charles ... Research – Business Development. , Charles is an accomplished and results-driven sales executive ...
(Date:7/10/2020)... BALTIMORE (PRWEB) , ... July ... ... Baltimore biotechnology company, announced today that Massachusetts Institute of Technology (MIT) has ... This broader license allows PathSensors to move into the point-of-care diagnostic market, ...
(Date:7/10/2020)... ... July 09, 2020 , ... Sentien Biotechnologies, Inc., ... hiring of Allen R. Nissenson, M.D., F.A.C.P., as its Chief Medical Officer. ... Sentien’s lead product, SBI-101. Dr. Nissenson serves as an Emeritus Professor of ...
(Date:7/7/2020)... ... July 06, 2020 , ... ... Entries from Roche, Eli Lilly, Bristol-Myers Squibb, the University of Chicago, Massachusetts General ... World has hosted an elite awards program, highlighting outstanding examples of how technology ...
Breaking Biology Technology:
Cached News: